Changes in Matrix Metalloproteinase (MMP) and Tissue Inhibitors of Metalloproteinases (TIMP) Expression Profile in Crohn's Disease After Immunosuppressive Treatment Correlate with Histological Score and Calprotectin Values

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2009 Aug 5

PMID 19652986

Citations 20

Authors

Laura Makitalo

Taina Sipponen

Paivi Karkkainen

Kaija-Leena Kolho

Ulpu Saarialho-Kere

Affiliations

Soon will be listed here.

Abstract

Background: Matrix metalloproteinases (MMPs) constitute a family of enzymes capable of degrading various extracellular matrices (ECM) and basement membrane components playing a role in ECM turnover. They activate and degrade signaling molecules, such as cytokines and chemokines. MMPs are involved in inflammation and have been implicated in tissue degradation and repair occurring in inflammatory bowel disease. The aim of this study was to investigate the MMP profile of intestinal Crohn's disease (CD) patients before and after immunosuppressive treatment (anti-TNF-alpha agents or corticosteroids and conventional immunosuppressants azathioprine or methotrexate) to learn more about the therapeutic pathways for immunosuppressive agents.

Methods: Expression of MMP-1, MMP-7, MMP-9, MMP-10, and MMP-26 and tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-3 was studied by immunohistochemistry in pretreatment and post-treatment tissue samples. Semiquantitative immunohistochemical scores were tested for correlations with fecal and serum inflammation markers as well as endoscopic and clinical disease activity scores.

Results: Neutrophil MMP-9 (p = 0.039) and MMP-26 (p = 0.030) and stromal TIMP-1 (p = 0.041) and TIMP-3 (p = 0.029) decreased along with treatment. However, expression of TIMP-3 by enterocytes tended to increase. Total histological score demonstrated positive correlation with neutrophil MMP-9 (p = 0.000), MMP-26 (p = 0.014), and macrophage TIMP-1 (p = 0.001). Calprotectin followed a similar pattern with stromal MMP-26 (p = 0.011), TIMP-1 (p = 0.000), and TIMP-3 (p = 0.001). Crohn's disease endoscopic index of severity (CDEIS) value correlated positively with macrophage TIMP-1 (p = 0.007) and stromal TIMP-3 (p = 0.005). Epithelial TIMP-3 presented with negative correlations with CDEIS (p = 0.006) and C-reactive protein values (p = 0.004).

Conclusions: Our results suggest that immunosuppressive drugs modulate disease activity in CD by downregulation of MMP-9 and MMP-26 positive neutrophils and stromal TIMP-1 and TIMP-3.

Citing Articles

Matrix metalloproteinases in intestinal fibrosis.

Biel C, Faber K, Bank R, Olinga P J Crohns Colitis. 2023; 18(3):462-478.

PMID: 37878770 PMC: 10906956. DOI: 10.1093/ecco-jcc/jjad178.

Anti-Inflammatory Effects of Dietary Polyphenols through Inhibitory Activity against Metalloproteinases.

Suzuki T, Ohishi T, Tanabe H, Miyoshi N, Nakamura Y Molecules. 2023; 28(14).

PMID: 37513300 PMC: 10385587. DOI: 10.3390/molecules28145426.

Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Alrubia S, Mao J, Chen Y, Barber J, Rostami-Hodjegan A Clin Pharmacokinet. 2022; 61(10):1365-1392.

PMID: 36056298 PMC: 9553790. DOI: 10.1007/s40262-022-01169-4.

Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort.

Vatn S, Lindstrom J, Moen A, Brackmann S, Tannaes T, Olbjorn C Clin Exp Gastroenterol. 2022; 15:5-25.

PMID: 35185343 PMC: 8848803. DOI: 10.2147/CEG.S343468.

The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases.

Derkacz A, Olczyk P, Olczyk K, Komosinska-Vassev K J Clin Med. 2021; 10(5).

PMID: 33800267 PMC: 7962650. DOI: 10.3390/jcm10051122.

References

Manfredi M, Zurakowski D, Rufo P, Walker T, Fox V, Moses M . Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14(8):1091-6. DOI: 10.1002/ibd.20419. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

Shanahan F . Crohn's disease. Lancet. 2002; 359(9300):62-9. DOI: 10.1016/S0140-6736(02)07284-7. View

Pender S, Li C, di Sabatino A, Sabatino A, MacDonald T, Buckley M . Role of macrophage metalloelastase in gut inflammation. Ann N Y Acad Sci. 2006; 1072:386-8. DOI: 10.1196/annals.1326.019. View

Gill S, Parks W . Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol. 2007; 40(6-7):1334-47. PMC: 2746915. DOI: 10.1016/j.biocel.2007.10.024. View

Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T . The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003; 38(4):348-54. DOI: 10.1007/s005350300062. View

Kolho K, Raivio T, Lindahl H, Savilahti E . Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006; 41(6):720-5. DOI: 10.1080/00365520500419623. View

Bister V, Salmela M, Heikkila P, Anttila A, Rintala R, Isaka K . Matrilysins-1 and -2 (MMP-7 and -26) and metalloelastase (MMP-12), unlike MMP-19, are up-regulated in necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 2004; 40(1):60-6. DOI: 10.1097/00005176-200501000-00011. View

Podolsky D . Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. DOI: 10.1056/NEJMra020831. View

10.

Meijer M, Mieremet-Ooms M, van Hogezand R, Lamers C, Hommes D, Verspaget H . Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007; 13(21):2960-6. PMC: 4171149. DOI: 10.3748/wjg.v13.i21.2960. View

11.

Isaka K, Nishi H, Nakai H, Nakada T, Li Y, Ebihara Y . Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer. 2002; 97(1):79-89. DOI: 10.1002/cncr.11030. View

12.

Kirkegaard T, Hansen A, BRUUN E, Brynskov J . Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004; 53(5):701-9. PMC: 1774029. DOI: 10.1136/gut.2003.017442. View

13.

Heuschkel R, MacDonald T, Monteleone G, Bajaj-Elliott M, Smith J, Pender S . Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000; 47(1):57-62. PMC: 1727949. DOI: 10.1136/gut.47.1.57. View

14.

Ravi A, Garg P, Sitaraman S . Matrix metalloproteinases in inflammatory bowel disease: boon or a bane?. Inflamm Bowel Dis. 2007; 13(1):97-107. DOI: 10.1002/ibd.20011. View

15.

Vandooren B, Kruithof E, Yu D, Rihl M, Gu J, De Rycke L . Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. 2004; 50(9):2942-53. DOI: 10.1002/art.20477. View

16.

Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer S, Stallmach A . Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis. 2007; 13(1):65-70. DOI: 10.1002/ibd.20012. View

17.

Meijer M, Mieremet-Ooms M, van Duijn W, van der Zon A, Hanemaaijer R, Verheijen J . Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13(2):200-10. DOI: 10.1002/ibd.20051. View

18.

Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer S . Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis. 2003; 19(4):308-15. DOI: 10.1007/s00384-003-0554-4. View

19.

Stumpf M, Cao W, Klinge U, Klosterhalfen B, Junge K, Krones C . Reduced expression of collagen type I and increased expression of matrix metalloproteinases 1 in patients with Crohn's disease. J Invest Surg. 2005; 18(1):33-8. DOI: 10.1080/08941930590905198. View

20.

Gao Q, Meijer M, Schluter U, van Hogezand R, van der Zon J, van den Berg M . Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis. 2007; 13(6):693-702. DOI: 10.1002/ibd.20100. View